Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page's revision tag changed from v3.5.3 to v3.5.4, indicating a minor platform update. There is no evidence of changes to the study details or other content on the page.
    Difference
    0.1%
    Check dated 2026-05-15T03:14:37.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    A bibliographic citation was added referencing the 2012 NEJM article 'Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.' This background reference situates the trial within the broader PD-L1 inhibitor literature.
    Difference
    0.1%
    Check dated 2026-05-07T23:13:02.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    Revision updated from v3.5.2 to v3.5.3, signaling a new release of the page content. This update represents a metadata/version change rather than substantive changes to the study details.
    Difference
    0.1%
    Check dated 2026-04-30T17:33:09.000Z thumbnail image
  4. Check
    22 days ago
    No Change Detected
  5. Check
    29 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2 and removed an older NEJM trial citation from the page; no substantive study details, eligibility criteria, or outcomes were altered.
    Difference
    0.1%
    Check dated 2026-04-16T10:30:29.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.3 to v3.5.0 at the top of the page. This is a minor version update that does not alter study details.
    Difference
    0.1%
    Check dated 2026-03-25T20:52:09.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3. The visible study content and layout remain unchanged.
    Difference
    0.1%
    Check dated 2026-03-11T17:28:18.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.